DOCSLIB.ORG

207620Orig1s000

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
207620Orig1s000 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207620Orig1s000 MEDICAL REVIEW(S) DNP Clinical Consult Memo NOA 207620 Sponsor: Novartis Drug: LCZ696 (Entresto) Proposed Indication: Heart Failure (NYHA class 11-IV) Material Submitted: NOA submission Consult Request Date: 6/29/15 Date Review Completed: 6/30/15 Clinical Reviewer: Teresa Buracchio, M.D. Nonclinical Reviewer: David B. Hawver, Ph.D. Clinical Team Lead: Nick Kozauer, M.D. Nonclinical Supervisor: Lois M. Freed, Ph.D. Division Director: Billy Dunn, M.D. DCRP has requested a consult from DNP to provide assistance in evaluating the theoretical potential for LCZ696 (Entresto) to increase the risk of developing Alzheimer's disease (AD). This memo will briefly summarize the relevant data discussed in the DCRP New Drug Application (NOA) reviews and will focus primarily on responding to the consult questions provided to DNP. Background: Heart failure (HF) is a major cause of morbidity and mortality in the United 1 States. It is estimated that over half of HF patients die within 5 years of diagnosis. .. 4 Novartis has studied LCZ696 for the treatment of heart failure (NYHA class II-IV) <b>< > (b)(4 . LCZ696 is a dual angiotensm receptor neprilysin Inhibitor (A~l\l i ) that dissociates into valsartan, an angiotensin receptor (AT1 ) blocker (ARB), and the pro-drug sacubitril (AHU377) following oral administration. Sacubitril is rapidly hydrolyzed in vivo to the active neprilysin inhibitor LBQ657. Neprilysin is an enzyme that degrades natriuretic peptides and vasoactive peptides. Neprilysin is also one of the major enzymes that breaks down the amyloid beta (Al3) peptide, a pathological marker of Alzheimer's disease, in the central nervous system. While showing benefit in the treatment of heart failure, it is theorized that inhibition of neprilysin could potentially increase levels of Al3 in the brain and CSF and increase the risk of developing AD. The following documents were reviewed for this consult: Clinical Pharmacology review by Luning Zhuang and Sreedharan Sabarinath; Clinical review by Kimberly Smith and 4 Tzu-Yun McDowell; a synopsis of Study <b>< I (focusing on cognitive 4 outcomes (bJ< >) submitted by the Sponsor. Study A2126, Phase 1 study AP in CSF: As stated in the Clinical Pharmacology review by Ors. Zhuang and Sabarinath, this was a placebo-controlled study in healthy subjects that examined the PK and PD effects of 400mg LCZ696 once daily for 14 days. At Day 14, there was about 50% increase in plasma Al3 1-40 (AUEC0_36h) with LCZ696 relative to placebo but there was no difference from placebo in the CSF. However, Al3 1-38 1 Go et al. Circulation. 2013;127:e6-e245 Reference ID: 3786906 Teresa Buracchio, MD, HFD-120 Medical Review Page 2 of 6 NDA 207620, LCZ696 (Entresto), Novartis 6/30/15 AUEC0_36h increased from baseline with LCZ696 by about 42% relative to placebo in the CSF. There was no significant difference with LCZ696 for amyloid-13 1-42 in CSF. It was estimated that blood brain barrier (BBB) penetrance for LZC696 was approximately 0.3%. PARADIGM-HF, Phase 3 study pivotal study: This was a multicenter, randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril in patients with HF (NYHA class 11- IV) and reduced ejection fraction (LVEF::535%). The study was stopped early after a median of 27 months of follow-up after the third interim analysis showed benefit on the primary endpoint, a composite of cardiovascular death or first heart failure hospitalization. From the clinical reviews by Dr. McDowell and Smith, the study enrolled 8442 patients age 18 years and older. The mean age of the study subjects was 64 years with a range of 18-96 years, 4229 patients in the enalapril arm and 4203 patients in the LCZ696. Approximately 50% of the patients were age 2:65 years with 20% of all patients ;::75 years of age. Patients were evenly distributed between the two treatment arms with regard to age. Dementia and cognitive function were not prospectively assessed in the study or identified as adverse events of special interest. Dementia-related events were captured through standard adverse event (AE) collection. Dementia-related events using the broad Standard MEDORA Query (SMQ) were seen equally in only 2% of patients in each treatment arm (Table 77 in the Clinical Review). This analysis used a broad search strategy which included preferred terms (PTs) such as "feeling abnormal" or "initial insomnia" that do not necessarily indicate dementia or cognitive impairment. For the narrow dementia SMQ which focuses on dementia diagnostic PTs, there were a total of 15/4229 (0.004%) dementia adverse events in the enalapril arm and 12/4203 (0.003%) in the LCZ696 arm. Of note, there were only 2 reports of Dementia Alzheimer's Type in each treatment arm. Planned studies to assess cognition and amyloid The Sponsor plans to further investigate the effects of LCZ696 on cognitive testing and amyloid by including ~ . rellminary d1scuss1ons have occurred oelveen the Sponsor andlJCRP w 1t h'-re_s_p_e-ct·~t· _..o the design and goals of this trial. 4 4 The Sponsor is planning to conduct a l study, <bH r that will assess the r n ' impact of LCZ696 on cognitive testingL <bH4l as measured by positron emission tomography (PET) imaging. (b)(4~ \U/\'t/ While neprilysin inhibitors such as sacubitril can potentially increase Aj3 levels in the CNS, the impact of increasing Aj3 in the CNS and subsequent risks of AD are unknown. Although animal models of neprilysin deficiency have shown increased Aj3 brain accumulation, to date, neprolysin deficiency has not been identified as a significant causative factor in the pathophysiology of AD in humans and there have not been Reference ID: 3786906 Teresa Buracchio, MD, HFD-120 Medical Review Page 3 of 6 NDA 207620, LCZ696 (Entresto), Novartis 6/30/15 consistent findings in the association between single nucleotide polymorphisms in neprolysin genes and risk of AD.234 There are alternate clearance pathways and enzymes that participate in the breakdown of Al3 and it is possible that these alternate ....__ pathways may be able to compensate for any loss in neprilysin. (bH-0' __ The effect of a neprilysin inhibitor on Al3 in the CNS will depend on its ability to cross the BBB and it appears that a very small amount (0.3%) of LCZ696 crosses the BBB. It is unclear if this is sufficient to significantly elevate Al3 in the CNS. The Phase 1 PK/PD study suggests that LCZ696 may elevate some forms of Al3 in the CSF and plasma in the short-term, but the clinical significance of these findings is unclear. The effects of chronic administration of LCZ696 on Al3 in the CNS are unknown. However, it should be stressed that even if elevations of Al3 should occur with LCZ696, it is not known if these elevations would impact the risk of developing AD. It has become increasingly evident that disturbances in amyloid regulation are but one of a number of complex pathophysiologic changes that occur in AD. Co-morbidities such as cardiovascular disease can also contribute significantly to the onset of dementia in patients with AD pathology. As patients with HF frequently have some degree of cognitive impairment, it is even theoretically possible that LCZ696 could have a positive benefit on the vascular contributions to dementia that may balance or outweigh the potential risk of increasing Aj3. 4 A signal for dementia risk was not identified for the <bH I study; however, the study was not designed to assess dementia or cognitive ou comes. As noted in the Clinical review, dementia and cognitive impairment were captured as adverse events but were not identified as Adverse Events of Special Interest so there is a possibility that these events may be underreported. Additionally, a median follow-up of 27 months would not be long enough to capture a significant number of incident cases of AD which can have a long latency period. Although there were limitations in the study design for ascertainment of dementia, this was a large study with approximately half of the patients age ~65 years who are at risk of developing dementia by virtue of age. There was not an imbalance in events seen between the treatment groups in either narrow or broad SMQ analyses for dementia to suggest a signal for increased risk of dementia or cognitive impairment with LCZ696. At this point there is no cl inical evidence to suggest that there is a risk for increasing development of AD or cognitive impairment with use of LCZ696 in this population of HF 4 patients with low ejection fraction. The Sponsor's plan to further evaluate the >1 ! study and a cognitive test battery and <1>mr PET imaging 4 (b>< study are reasonable as additional steps for assessing any impact of LGZ696--- on cognition and amyloid pathology. 2Vodovar et al. Eur Heart J. 2015;36:902-5. 3 http://www.alzforum.org/news/research-news/inhibiting-neprilysin-good-heart-what-about-brain. Accessed June 30, 2015 4 Xingzhi et al. J Neurol Sci 2014; 346:6-10. Reference ID: 3786906 Teresa Buracchio, MD, HFD-120 Medical Review Page 4 of 6 NDA 207620, LCZ696 (Entresto), Novartis 6/30/15 DCRP Questions 1. Dr. Link (DCRP pharmacology-toxicology reviewer) reviewed the evidence that neprilysin breaks down beta amyloid (see attached). Do you agree with his assessment of the evidence that neprilysin breaks down beta amyloid? We agree with Dr. Link’s view that the evidence supports a role for neprilysin as one of the primary Aβ degrading enzymes (of more than a dozen enzymes identified to date) that are involved in clearance of Aβ from the brain.
Load more

Recommended publications
  • Pediatric Suprasellar Germ Cell Tumors: a Clinical and Radiographic Review of Solitary Vs
    cancers Article Pediatric Suprasellar Germ Cell Tumors: A Clinical and Radiographic Review of Solitary vs. Bifocal Tumors and Its Therapeutic Implications Darian R. Esfahani 1 , Tord Alden 1,2, Arthur DiPatri 1,2, Guifa Xi 1,2, Stewart Goldman 3 and Tadanori Tomita 1,2,* 1 Division of Pediatric Neurosurgery, Ann & Robert H. Lurie Children’s Hospital, Chicago, IL 60611, USA; [email protected] (D.R.E.); [email protected] (T.A.); [email protected] (A.D.); [email protected] (G.X.) 2 Department of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA 3 Division of Hematology, Oncology, Neuro-Oncology & Stem Cell Transplantation, Ann & Robert H. Lurie Children’s Hospital, Chicago, IL 60611, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-312-2274220 Received: 7 August 2020; Accepted: 10 September 2020; Published: 14 September 2020 Simple Summary: Bifocal suprasellar germ cell tumors are a unique type of an uncommon brain tumor in children. Compared to other germ cell tumors in the brain, bifocal tumors are poorly understood and have a bad prognosis. In this paper we explore features that predict which children will have good outcomes and which will not. This is important for the research community because it can help physicians decide what type of radiation treatment is best to treat these children. Our study shows that bifocal tumors have a unique appearance on magnetic resonance imaging (MRI) compared to other germ cell tumors. Children with bifocal tumors are more likely to be male, have tumors that come back sooner, and cause death sooner.
    [Show full text]
  • Drug Class Review Antianginal Agents
    Drug Class Review Antianginal Agents 24:12.08 Nitrates and Nitrites 24:04.92 Cardiac Drugs, Miscellaneous Amyl Nitrite Isosorbide Dinitrate (IsoDitrate ER®, others) Isosorbide Mononitrate (Imdur®) Nitroglycerin (Minitran®, Nitrostat®, others) Ranolazine (Ranexa®) Final Report May 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Antianginal Therapies .............................................................................................. 4 Table 2. Summary of Agents .................................................................................................. 5 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Clinical Practice Guidelines .................................................... 9 Pharmacology ............................................................................................................................... 10 Table 4. Pharmacokinetic Properties
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Hospital Medical School.)
    THE CONTROL OF THE SUPRARENAL GLANDS BY THE SPLANCHNIC NERVES'. BY T. R. ELLIOTT, M.D. (From the Research Laboratories of University College, Hospital Medical School.) THERE is no clear knowledge2 at present with regard to the share taken by the suprarenal glands in resisting various processes that are harmful to the body. For the last two years I have tried to gain some light on this question by analysing the state of exhaustion to which the human suprarenals are reduced in the different conditions leading to death in Hospital cases. Attention was paid chiefly to the loss of the normal load of cortical " lipoid " substance and of the adrenalin in the medulla, the gross total of the latter being measured quantitatively by physio- logical assay. Unfortunately the conditions of fatal disease in man were found to be too complex to permit of simple atialysis. Broadly summarising the results, it appeared that the glands suffered rapid eyhaustion in cases of any microbic fever, of repeated simple hawmorrhage, and of surgical shock: but to distinguish clearly the value and nature of each of these factors was impossible. I therefore tried to reproduce each separately on experimental animals, in which the relationship of the nervous system to the glands could at the same time be studied. Method. Cats were used in all the experiments. The lipoid in the cortex of the cat3 is never so abundant as in the human gland: changes in its distribution were observed histologically, but they did not seem to follow any special cause, and they will be referred to only incidentally in this paper.
    [Show full text]
  • Case Reports
    CASE REPORTS NONCHROMAFFIN PARAGANGLIOMA OF THE JUGULAR FORAMEN Jos~ G. ALBERNAZ,M.D.,* A:N'D PAUL C. BucY, M.D. Chicago Memorial Hospital and Department of Neurology and Neurological Surgery, University of Illinois, College of Medicine, Chicago, Illinois (Received for publication April 7, 1953) This paper deals with a carotid-body-like tumor found in the jugular foramen, similar to the tumors recently described by Lattes 12 as nouchromaffin paraganglio- mas. Kohn, 1~ in 1900, classified the carotid body as a paraganglion, in the belief that it was of sympathetic origin and part of the chromaffin system. Small masses of similar paraganglionic tissue have since been described in the following locations: 1) At the level of the middle ear. As early as 1840, Valentin 26 described a gangliolum tympanicum, associated with the tympanic branch of the 9th cranial nerve. Later, in 1879, Krause H showed that this structure resembles the carotid body and this has been confirmed recently by the studies of Guild s and Lattes and WaltnerY In addi- tion to the paraganglion tympanicum, Guild s described what he called the glomus jugularis "in the adventitia of the dome of the jugular bulb, immediately below the bony floor of the middle ear." ~) At the aortic-pulmonary region. Paraganglia related to the major vessels at the base of the heart were mentioned in 190~ by Biedl and Wiesel. 2 In the middle thirties, Palme, 2~ Seto, 24 Muratori ~9 and Nonidez 2~ described these structures in detail. From their contributions, well summarized by Boyd, 4 we learn that these "aortic bodies" are similar to the carotid bodies and that they can be found in four different locations: a) above the ductus arteriosus; b) on the trunk of the pulmonary artery, near the origin of the left coronary artery; c) near the root of the innominate artery; d) on the left part of the aortic arch.
    [Show full text]
  • Clinical Radiation Oncology Review
    Clinical Radiation Oncology Review Daniel M. Trifiletti University of Virginia Disclaimer: The following is meant to serve as a brief review of information in preparation for board examinations in Radiation Oncology and allow for an open-access, printable, updatable resource for trainees. Recommendations are briefly summarized, vary by institution, and there may be errors. NCCN guidelines are taken from 2014 and may be out-dated. This should be taken into consideration when reading. 1 Table of Contents 1) Pediatrics 6) Gastrointestinal a) Rhabdomyosarcoma a) Esophageal Cancer b) Ewings Sarcoma b) Gastric Cancer c) Wilms Tumor c) Pancreatic Cancer d) Neuroblastoma d) Hepatocellular Carcinoma e) Retinoblastoma e) Colorectal cancer f) Medulloblastoma f) Anal Cancer g) Epndymoma h) Germ cell, Non-Germ cell tumors, Pineal tumors 7) Genitourinary i) Craniopharyngioma a) Prostate Cancer j) Brainstem Glioma i) Low Risk Prostate Cancer & Brachytherapy ii) Intermediate/High Risk Prostate Cancer 2) Central Nervous System iii) Adjuvant/Salvage & Metastatic Prostate Cancer a) Low Grade Glioma b) Bladder Cancer b) High Grade Glioma c) Renal Cell Cancer c) Primary CNS lymphoma d) Urethral Cancer d) Meningioma e) Testicular Cancer e) Pituitary Tumor f) Penile Cancer 3) Head and Neck 8) Gynecologic a) Ocular Melanoma a) Cervical Cancer b) Nasopharyngeal Cancer b) Endometrial Cancer c) Paranasal Sinus Cancer c) Uterine Sarcoma d) Oral Cavity Cancer d) Vulvar Cancer e) Oropharyngeal Cancer e) Vaginal Cancer f) Salivary Gland Cancer f) Ovarian Cancer & Fallopian
    [Show full text]
  • The Diagnosis and Pathological Value of Combined Detection of HE4 and CA125 for Patients with Ovarian Cancer
    Open Med. 2016; 11:125-132 Research Article Open Access Li-e Zheng*, Jun-ying Qu, Fei He The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer DOI 10.1515/med-2016-0024 other. Conclusion HE4 can be used as a novel clinical bio- received January 28, 2016; accepted March 9, 2016 marker for predicting malignant ovarian tumors and its expression was closely related with the clinical pathologi- Abstract: Objective To evaluate the value of individual and cal features of malignant ovarian tumors. combined measurement of human epididymis protein 4 (HE4) and cancer antigen 125 (CA-125) in the diagnosis Keywords: HE4; CA125; diagnosis; ovarian tumor of ovarian cancer. Methods A clinical case-control study was performed in which the levels of serum HE4 and CA-125 of subjects with malignant, borderline, benign ovarian tumors and healthy women were measured before 1 Introduction surgery. An immunohistochemistry method was used In the female reproductive system, ovarian cancer ranks to measure the expression of HE4 in different tissues. third in incidence and 1st in mortality in gynecological Statistical analysis was performed to determine the rela- malignancies [1]. Nearly 70% of patients with ovarian tionship between the level of HE4 and the pathologic cancer are diagnosed at an advanced stage, and the 5 year type as well as the stage of the ovarian tumors. Results survival rate for patients with ovarian cancer rises up to The level of HE4 in the serum was significantly elevated in 90% through early effective treatment [2]. Hence, diag- the malignant ovarian cancer group compared with other nosing at early stage is crucial to improve the prognosis of groups.
    [Show full text]
  • Heart Failure
    9/15/2010 HEART FAILURE PfProfessor LlLexley M MPitP Pinto Perei ra Pharmacology Unit Faculty of Medical Sciences UWI ST Augustine Acknowledgements : American Heart Association Sociedad Española de CardiologíaJune, 1999 Epidemiology • More in N Europe and USA • Increases with age esp in males > 75 • US Data • 5,000,000 patients • 6,500,000 hospital days/ year • 300,000 deaths / year • 6% --10%10% of people > 65 years • 5.4%f% of health care budget (38 billion) • Incidence x 2 in last ten years • Estimated prevalence 6 mio by 2030 Gottdiener J et al. JACC 2000;35:1628, Haldeman GA et al. Am Heart J 1999;137:352 Kannel WB et al. Am Heart J 1991;121:951, O’Connell JB et al. J Heart Lung Transplant 1993;13:S107, Young J, MCNA 2004; 1 9/15/2010 Definition of heart failure Clinical syyyndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood AHA / ACC HF guidelines 2001 Clinical symptoms / signs secondary to abnormal ventricular function ESC HF guidelines 2001 “Heart Failure” vs. “Congestive Heart Failure” All patients may NOT have volume overload at the time of initial or subsequent evaluation. Therefore the term “heart failure” is preferred over the older term “ihfil”“congestive heart failure.” CHF is a significant cause of morbidity and mortality Important cause of hospitalizations among elderly 2 9/15/2010 Causes of HF For a substantial proportion of patients, the causes of HF are: 1. Coronary artery disease 2. Hypertension 3. Dilated cardiomyopathy And there are other causes 1.
    [Show full text]
  • A Xenograft and Cell Line Model of SDH-Deficient Pheochromocytoma Derived from Sdhb+/− Rats
    27 6 Endocrine-Related J F Powers et al. Rat model for Sdhb-mutated 27:6 337–354 Cancer paraganglioma RESEARCH A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/− rats James F Powers1, Brent Cochran2, James D Baleja2, Hadley D Sikes3, Andrew D Pattison4, Xue Zhang2, Inna Lomakin1, Annette Shepard-Barry1, Karel Pacak5, Sun Jin Moon3, Troy F Langford3, Kassi Taylor Stein3, Richard W Tothill4,6, Yingbin Ouyang7 and Arthur S Tischler1 1Department of Pathology and Laboratory Medicine, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA 2Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, Boston, Massachusetts, USA 3Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA 4Department of Clinical Pathology, University of Melbourne, Melbourne, Victoria, Australia 5Section on Medical Neuroendocrinology, Eunice Kennedy Shriver Division National Institute of Child Health and Human Development, Bethesda, Maryland, USA 6Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia 7Cyagen US Inc, Santa Clara, California, USA Correspondence should be addressed to J F Powers: [email protected] Abstract Tumors caused by loss-of-function mutations in genes encoding TCA cycle enzymes Key Words have been recently discovered and are now of great interest. Mutations in succinate f succinate dehydrogenase B dehydrogenase (SDH) subunits cause pheochromocytoma/paraganglioma (PCPG) and f paraganglioma syndromically associated tumors, which differ phenotypically and clinically from more f pheochromocytoma common SDH-intact tumors of the same types. Consequences of SDH deficiency include f cluster 1 rewired metabolism, pseudohypoxic signaling and altered redox balance. PCPG with f xenograft SDHB mutations are particularly aggressive, and development of treatments has been f cell culture hampered by lack of valid experimental models.
    [Show full text]
  • Opmaak 1 15/06/12 08:52 Pagina 124
    arain-_Opmaak 1 15/06/12 08:52 Pagina 124 JBR–BTR, 2012, 95: 124-125. PARAGANGLIOMA OF THE CAVERNOUS SINUS A. Arain, J. Vandevenne, B. Depeuter, J. Smits, F. Weyns, Y. Palmers 1 Key-word: Paraganglioma Background : A 15-year-old girl presented in a Dutch hospital with right-sided trigeminal neuralgia. MR-imaging showed a mass lesion in the right cavernous sinus. Differential diagnosis in this hospital was a meningioma or a schwannoma. The patient was referred to the neurosurgery department of our hospital, and resection of the lesion was planned. At surgery, the lesion pre - sented as a subdural bulge surrounded by swollen venous structures. The incision of the dura resulted in profuse hemorrhage of arterial origin, and hemostasis was obtained with difficulty. The tumor showed a fibrillar structure and a strong arterial vascularization which was not con - cordant with schwannoma. No further exploration of the lesion was performed, and no biopsy was obtained. To clarify the unexpected surgical findings and to reach a diagnosis without biopsy , pre-operative MR-images were reviewed. Digital subtraction angio graphy (DSA) was performed postoperatively. The lesion did not take up FDG on PET scan. Laboratory results showed increased catecholamines in the urine. AB CD E 1A 1B Fig. 1C 1D 1. Department of Medical Imaging, Campus Sint-Jan, Ziekenhuis Oost-Limburg, Genk, Belgium. 1E 2 arain-_Opmaak 1 15/06/12 08:52 Pagina 125 PARAGANGLIOMA OF THE CAVERNOUS SINUS — ARAIN et al 125 Work-up ly show a hyperintense signal on T2-weighted MR- images and a distinct contrast enhancement on T1- MRI of the brain (Fig.
    [Show full text]
  • Genitourinary Advanced Pca and Its Efficacy As a Therapeutic Agent Is Presently Being Studied in Clinical Trials
    ANNUAL MEETING ABSTRACTS 133A because they were over age 80 and as such, the IHC results were likely due to acquired 599 Anterior Predominant Prostate Tumors: A Contemporary methylation of the MLH1 promoter. The remaining 4 patients with absent staining have Look at Zone of Origin been referred to Cancer Genetics for possible further work-up. The reimbursement rate HA Al-Ahmadie, SK Tickoo, A Gopalan, S Olgac, VE Reuter, SW Fine. Memorial Sloan and turn-around time for the IHC stains were similar to that for other IHC stains used Kettering Cancer Center, NY, NY. in clinical practice. Background: Aggressive PSA screening and prostate needle biopsy protocols have Conclusions: IHC stains for the MMR proteins are fast and relatively easy to institute in successfully detected low-volume posterior tumors, with a concurrent increase in routine evaluation of CRC, and we have not had difficulty interpreting the stains leading anterior-predominant prostate cancer (AT). Zone of origin, patterns of spread, and to additional testing. Furthermore, reimbursement was obtained at a level similar to extraprostatic extension of these tumors have not been well studied. other IHC stains used in clinical practice. The surgeons and oncologists welcomed the Design: We greatly expanded and refined our previous studies to include pathologic prognostic information. Further study is warranted to confirm these initial findings. features of 197 patients with largest tumors anterior to the urethra in whole-mounted radical prostatectomy specimens. 597 High Fidelity Image Cytometry in Neoplastic Lesions in Barrett’s Results: Of 197 AT, 97 (49.2%) were predominantly located in the peripheral zone Esophagus, Including Basal Crypt Dysplasia-Like Atypia with Surface (PZ-D), 70 (35.5%) in the transition zone (TZ-D), 16 (8.1%) were of indeterminate Maturation zone (IND), and 14 (7.1%) in both PZ and TZ (PZ+TZ).
    [Show full text]
  • In February 2013, Glaxosmithkline (GSK) Announced a Commitment To
    In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register. The following guiding principles have been applied to the disclosure: Information will be excluded in order to protect the privacy of patients and all named persons associated with the study Patient data listings will be completely removed* to protect patient privacy. Anonymized data from each patient may be made available subject to an approved research proposal. For further information please see the Patient Level Data section of the GSK Clincal Study Register. Aggregate data will be included; with any direct reference to individual patients excluded *Complete removal of patient data listings may mean that page numbers are no longer consecutively numbered CONFIDENTIAL GM2004/00056/00GM2004/00056/00 SAM40040SAM40040 The GlaxoSmithKline group of companies A twenty-four week, randomised, double-dummy, double-blind, parallel group study to compare the occurrence of exacerbations between SERETIDE DISKUS 50/250µg 1 inhalation bd and formoterol/budesonide Breath-Actuated Dry Powder Inhaler 4.5/160µg 2 inhalations bd in subjects with moderate to severe asthma. Clinical Study Report for Study SAM40040 (Development Phase IV) Document Number: GM2004/00056/00 Compound Number: CCI18781/ GR33343 Investigational Product: SERETIDE Generic Drug Name: salmeterol/fluticasone propionate combination Indication Studied: Asthma Initiation Date: 26 Nov 2001 Completion Date: 13 Jan 2003 Early Termination Date: N/A Date of Report: August 2004 Sponsor Signatory: (and Medical Officer) Vice President European Clinical Respiratory Medicines Development Centre This study was performed in compliance with Good Clinical Practices including the archiving of essential documents.
    [Show full text]